X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ASTRAZENECA PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ASTRAZENECA PHARMA SUN PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 46.9 141.9 33.1% View Chart
P/BV x 3.8 21.5 17.6% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUN PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
ASTRAZENECA PHARMA
Mar-14
SUN PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs8421,285 65.5%   
Low Rs572634 90.3%   
Sales per share (Unadj.) Rs131.6189.6 69.4%  
Earnings per share (Unadj.) Rs32.7-0.2 -16,062.2%  
Cash flow per share (Unadj.) Rs38.03.8 987.8%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs152.768.6 222.5%  
Shares outstanding (eoy) m2,399.2625.00 9,597.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.45.1 106.2%   
Avg P/E ratio x21.6-4,712.7 -0.5%  
P/CF ratio (eoy) x18.6249.6 7.5%  
Price / Book Value ratio x4.614.0 33.1%  
Dividend payout %10.70-   
Avg Mkt Cap Rs m1,696,87723,988 7,074.0%   
No. of employees `00017.51.6 1,123.5%   
Total wages/salary Rs m49,0231,605 3,055.2%   
Avg. sales/employee Rs Th18,028.33,040.2 593.0%   
Avg. wages/employee Rs Th2,798.81,029.2 271.9%   
Avg. net profit/employee Rs Th4,479.5-3.3 -137,200.1%   
INCOME DATA
Net Sales Rs m315,7844,740 6,662.5%  
Other income Rs m6,23292 6,766.0%   
Total revenues Rs m322,0164,832 6,664.5%   
Gross profit Rs m100,893-130 -77,729.4%  
Depreciation Rs m12,648101 12,497.5%   
Interest Rs m3,9980-   
Profit before tax Rs m90,479-139 -65,139.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m12,1165 238,029.5%   
Profit after tax Rs m78,462-5 -1,541,499.0%  
Gross profit margin %31.9-2.7 -1,166.7%  
Effective tax rate %13.4-3.7 -365.4%   
Net profit margin %24.8-0.1 -23,136.9%  
BALANCE SHEET DATA
Current assets Rs m329,5372,726 12,086.9%   
Current liabilities Rs m178,8702,435 7,345.8%   
Net working cap to sales %47.76.1 776.0%  
Current ratio x1.81.1 164.5%  
Inventory Days Days7974 107.1%  
Debtors Days Days8341 204.2%  
Net fixed assets Rs m204,7661,035 19,778.4%   
Share capital Rs m2,39950 4,798.6%   
"Free" reserves Rs m363,997942 38,624.5%   
Net worth Rs m366,3971,716 21,351.8%   
Long term debt Rs m14,3610-   
Total assets Rs m614,1024,156 14,776.3%  
Interest coverage x23.6NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.51.1 45.1%   
Return on assets %13.4-0.1 -10,963.8%  
Return on equity %21.4-0.3 -7,219.5%  
Return on capital %24.80-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m44,118375 11,777.4%   
Fx outflow Rs m24,484470 5,207.7%   
Net fx Rs m19,634-96 -20,548.4%   
CASH FLOW
From Operations Rs m70,822-8 -874,346.9%  
From Investments Rs m-42,216-146 28,974.6%  
From Financial Activity Rs m-22,854862 -2,650.6%  
Net Cashflow Rs m6,107709 861.9%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 0.3 1,710.0%  
FIIs % 23.0 15.7 146.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 9.1 91.2%  
Shareholders   133,026 12,856 1,034.7%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 22, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - NATCO PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS